BRK is a member of the non-receptor tyrosine kinases (PTKs) that contains an amino terminal SH3 and SH2 domain as well as the catalytic domain. BRK expression is low or undetectable in normal mammary tissue and benign lesions. However, approximately two-thirds of breast tumors express appreciable levels, and 27% of tumors over express BRK by fivefold or more. Source: Recombinant protein corresponding to aa2-451 from human BRK, fused to GST-tag at N-terminal, expressed in Sf9 insect cells. Molecular Weight: ~80kD Specific Activity: 88pmol/min/ug Applications: Suitable for use in the study of enzyme kinetics, screening inhibitors, and selectivity profiling. Other applications not tested. Recommended Dilution: Optimal dilutions to be determined by the researcher. Assay Conditions: Enzyme reaction was conducted in a buffer (25ul) containing 40mM Tris-HCl, pH 7.5, 20mM MgCl2, 100um ATP, 0.2mg/ml poly-(Glu, Tyr), and BRK for 40 min at 30°C. Storage and Stability: Aliquot to avoid repeated freezing and thawing and store at -70C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
